Knight Therapeutics Inc.

TSX:GUD Stock Report

Market Cap: CA$583.8m

Knight Therapeutics Management

Management criteria checks 3/4

Knight Therapeutics' CEO is Samira Sakhia, appointed in Aug 2016, has a tenure of 7.75 years. total yearly compensation is CA$1.17M, comprised of 40.1% salary and 59.9% bonuses, including company stock and options. directly owns 0.25% of the company’s shares, worth CA$1.46M. The average tenure of the management team and the board of directors is 2.9 years and 7.8 years respectively.

Key information

Samira Sakhia

Chief executive officer

CA$1.2m

Total compensation

CEO salary percentage40.1%
CEO tenure7.8yrs
CEO ownership0.2%
Management average tenure2.9yrs
Board average tenure7.8yrs

Recent management updates

Recent updates

Does Knight Therapeutics (TSE:GUD) Have A Healthy Balance Sheet?

May 28
Does Knight Therapeutics (TSE:GUD) Have A Healthy Balance Sheet?

Shareholders May Not Be So Generous With Knight Therapeutics Inc.'s (TSE:GUD) CEO Compensation And Here's Why

May 07
Shareholders May Not Be So Generous With Knight Therapeutics Inc.'s (TSE:GUD) CEO Compensation And Here's Why

Calculating The Fair Value Of Knight Therapeutics Inc. (TSE:GUD)

Apr 07
Calculating The Fair Value Of Knight Therapeutics Inc. (TSE:GUD)

Read This Before Selling Knight Therapeutics Inc. (TSE:GUD) Shares

Mar 20
Read This Before Selling Knight Therapeutics Inc. (TSE:GUD) Shares

If You Had Bought Knight Therapeutics' (TSE:GUD) Shares Three Years Ago You Would Be Down 34%

Mar 02
If You Had Bought Knight Therapeutics' (TSE:GUD) Shares Three Years Ago You Would Be Down 34%

Knight Therapeutics (TSE:GUD) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Feb 03
Knight Therapeutics (TSE:GUD) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Knight Therapeutics's (TSE:GUD) Earnings Are Growing But Is There More To The Story?

Jan 19
Knight Therapeutics's (TSE:GUD) Earnings Are Growing But Is There More To The Story?

What Type Of Shareholders Own The Most Number of Knight Therapeutics Inc. (TSE:GUD) Shares?

Jan 04
What Type Of Shareholders Own The Most Number of Knight Therapeutics Inc. (TSE:GUD) Shares?

A Look At The Fair Value Of Knight Therapeutics Inc. (TSE:GUD)

Dec 20
A Look At The Fair Value Of Knight Therapeutics Inc. (TSE:GUD)

The Founder of Knight Therapeutics Inc. (TSE:GUD), Jonathan Goodman, Just Bought A Few More Shares

Dec 07
The Founder of Knight Therapeutics Inc. (TSE:GUD), Jonathan Goodman, Just Bought A Few More Shares

What Type Of Returns Would Knight Therapeutics'(TSE:GUD) Shareholders Have Earned If They Purchased Their SharesYear Ago?

Dec 02
What Type Of Returns Would Knight Therapeutics'(TSE:GUD) Shareholders Have Earned If They Purchased Their SharesYear Ago?

Need To Know: The Consensus Just Cut Its Knight Therapeutics Inc. (TSE:GUD) Estimates For 2021

Nov 17
Need To Know: The Consensus Just Cut Its Knight Therapeutics Inc. (TSE:GUD) Estimates For 2021

CEO Compensation Analysis

How has Samira Sakhia's remuneration changed compared to Knight Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023n/an/a

-CA$17m

Sep 30 2023n/an/a

-CA$8m

Jun 30 2023n/an/a

-CA$16m

Mar 31 2023n/an/a

-CA$15m

Dec 31 2022CA$1mCA$468k

-CA$30m

Sep 30 2022n/an/a

-CA$23m

Jun 30 2022n/an/a

-CA$33m

Mar 31 2022n/an/a

-CA$7m

Dec 31 2021CA$1mCA$401k

CA$16m

Sep 30 2021n/an/a

CA$32m

Jun 30 2021n/an/a

CA$59m

Mar 31 2021n/an/a

CA$47m

Dec 31 2020CA$688kCA$298k

CA$42m

Sep 30 2020n/an/a

CA$27m

Jun 30 2020n/an/a

CA$6m

Mar 31 2020n/an/a

CA$8m

Dec 31 2019CA$987kCA$287k

CA$15m

Sep 30 2019n/an/a

CA$21m

Jun 30 2019n/an/a

CA$37m

Mar 31 2019n/an/a

CA$22m

Dec 31 2018CA$787kCA$267k

CA$24m

Sep 30 2018n/an/a

CA$31m

Jun 30 2018n/an/a

CA$22m

Mar 31 2018n/an/a

CA$18m

Dec 31 2017CA$438kCA$263k

CA$17m

Compensation vs Market: Samira's total compensation ($USD848.02K) is below average for companies of similar size in the Canadian market ($USD1.29M).

Compensation vs Earnings: Samira's compensation has increased whilst the company is unprofitable.


CEO

Samira Sakhia (55 yo)

7.8yrs

Tenure

CA$1,166,767

Compensation

Ms. Samira Sakhia, MBA, BCom, CPA, CA, has been the President at Knight Therapeutics Inc. since August 31, 2016 and served as its Chief Financial Officer since October 10, 2017 until March 30, 2020. She ha...


Leadership Team

NamePositionTenureCompensationOwnership
Jonathan Goodman
Executive Chairman11.3yrsCA$438.93k22.32%
CA$ 130.3m
Samira Sakhia
President7.8yrsCA$1.17m0.25%
CA$ 1.5m
Arvind Utchanah
Chief Financial Officer4.2yrsCA$801.68k0.039%
CA$ 225.8k
Amal Khouri
Chief Business Officer3.2yrsCA$719.09k0.15%
CA$ 878.3k
Jeff Martens
Global Vice President of Commercial3.6yrsCA$534.15kno data
Stephani Saverio
Vice President of Business Development3.1yrsCA$550.38kno data
Leopoldo Bosano
Vice-President of Manufacturing & Operations2.2yrsno datano data
Monica Percario
Global Vice President of Scientific Affairsno datano datano data
Henrique Dias
Global Director of Marketing1.3yrsno data0.0016%
CA$ 9.2k
Susan Emblem
Global Vice President of Human Resources2.8yrsno data0.018%
CA$ 103.6k
Melanie Groleau
Global Vice President of Medical & Clinicalless than a yearno datano data

2.9yrs

Average Tenure

Experienced Management: GUD's management team is considered experienced (2.9 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Jonathan Goodman
Executive Chairman11.3yrsCA$438.93k22.32%
CA$ 130.3m
Samira Sakhia
President7.8yrsCA$1.17m0.25%
CA$ 1.5m
James Gale
Independent Lead Director11.3yrsCA$155.00k0.050%
CA$ 294.6k
Robert Lande
Independent Director10.3yrsCA$133.83k0.27%
CA$ 1.5m
Nicolas Sujoy
Independent Director3.9yrsCA$125.58k0.012%
CA$ 68.1k
Janice Murray
Independent Director3.9yrsCA$122.50k0.0084%
CA$ 49.0k
Michael Tremblay
Independent Director5yrsCA$115.00k0.0020%
CA$ 11.6k

7.8yrs

Average Tenure

57yo

Average Age

Experienced Board: GUD's board of directors are considered experienced (7.8 years average tenure).


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.